The Latest Breaking News from NVO

The healthcare industry is poised to grow significantly in the coming years. Moreover, as healthcare stocks tend to perform relatively well despite macro uncertainties due to inelastic demand for their products and services, high-flying pharma stocks Novo Nordisk (NVO), AbbVie (ABBV), and Merck & Co (MRK) might be ideal investments…

Novo Nordisk is planning to boost production for weight-loss shot Wegovy as Eli Lilly angles for approval. NVO stock surged Wednesday.

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

The stock market has witnessed significant volatility amid the record high inflation and the Fed’s hawkish stance on it. Investors have been banking on healthcare stocks as they tend to hold up relatively well in such turbulent times. We think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer…

The Fed’s hawkish stance on inflation, along with other macroeconomic issues, has created substantial market volatility. However, it might be better to stay invested to reap long-term returns. To that end, fundamentally sound stocks Novo Nordisk (NVO), Centene (CNC), McKesson (MCK), Universal Logistics (ULH), and Sisecam Resources (SIRE) might be…

Danish drugmaker Novo Nordisk missed quarterly views Wednesday, but raised its full-year outlook. Still, NVO stock tumbled.

Amid an uncertain market, it becomes increasingly difficult for investors to find stocks that can survive the challenges and deliver solid returns. Accel Entertainment (ACEL), Novo Nordisk (NVO), and Titan Machinery (TITN) are currently not on investors’ radar, but it could be worth adding these stocks to one’s portfolio given…

Fund ownership has been increasing at Alliance Resource in at least the past three quarters.

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 21.31%. Currently, Novo Nordisk has a market capitalization of $251.98 billion.

The inelastic demand and rising investments in research and development should drive the pharmaceutical industry’s growth in the long run. Therefore, pharmaceutical stocks AbbVie (ABBV), Amgen (AMGN), Catalyst (CPRX), Novo Nordisk (NVO), and Vertex (VRTX), which possess sound fundamentals, could be solid long-term investments. These stocks are rated Strong Buy…

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 14.11%. Currently, Novo Nordisk has a market capitalization of $238.19 billion.